Minoxidil and Kidney Health Concerns
Q. A few years back, I came across information on low-dose minoxidil and decided to get a prescription from my GP. Since then, I’ve been using it regularly. I noticed my fine hair was thinning during menopause, making it tough to even tie it back.
Now, I think my hair has increased by about 30% to 40% without any noticeable side effects. For the first time in ages, the hair along my face has filled in, so I don’t feel like I have to stick with a short fringe. It’s been quite a positive change, and I plan to keep taking 2.5 milligrams of minoxidil each day.
A. A recent systematic review analyzing 27 studies on this off-label usage of minoxidil found that between 35% to 47% of participants experienced enhanced hair growth (Frontiers in Pharmacology, June 3, 2025). Most side effects noted were minor, though some individuals did report unwanted hair growth, and a few mentioned swollen ankles. The dosage you’re using seems to align well with the effective doses highlighted in the review.
Originally, minoxidil was approved in 1979 specifically for high blood pressure treatment. The standard oral dosage ranges from 5 to 100 milligrams daily, but at those levels, side effects can be serious. However, low-dose minoxidil, which typically falls between 0.25 to 5 milligrams, is deemed much safer but still needs medical oversight.
Q. I’ve been on omeprazole for 25 years, and then out of the blue, I was diagnosed with stage 3 kidney disease about four years ago, with no other apparent risk factors.
I received treatment for the kidney disease with immunosuppressants and have been in remission for the last three years. When I brought up the potential link between proton pump inhibitors, like omeprazole, and kidney issues, my nephrologist just rolled his eyes. Yet, I still believe it played a role in my condition.
A. A systematic review focusing on proton pump inhibitors, including omeprazole, concluded: “PPIs are associated with the development of chronic kidney disease (CKD)” (Cureus, Dec. 3, 2023).
